Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-celloriginated protein kinase
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-056-Tuesday
- By: LI, Hua (Wuhan, China)
- Co-author(s): Mengzhu Zheng: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Suyu Gao: Wuya College of Innovation,School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
Shanshan Luan : School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Lixia Chen: Wuya College of Innovation,School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
Hua Li: School of Pharmacy, Tongji Medical College , Huazhong University of Science and Technology, Wuhan, China - Abstract:
Backgrounds
T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor.Aims
Discovery of a TOPK selective inhibitor which can suppress the growth of cancer cells.Methods
A series of methods were used, including in .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023